BioHarvest Sciences https://validator.w3.org/feed/docs/rss2.html Nutraceuticals BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026 BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results  BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026 BioHarvest Sciences Reports Second Quarter 2025 Financial Results 2026 CEO Letter to Shareholders BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale FAQ BioHarvest Sciences Issues Year End Shareholder Letter BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform BIOHARVEST SCIENCES ANNOUNCES CLOSING OF $19.9 MILLION UPSIZED PUBLIC OFFERING OF COMMON STOCK AND EXERCISE OF UNDERWRITER’S OPTION TO PURCHASE ADDITIONAL SHARES BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time Pharmaceuticals BioHarvest Sciences Reports Third Quarter 2025 Financial Results BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and additional $3.8 Million in Debt Reduction BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET BioHarvest Sciences to Present at Canaccord Genuity 45th Annual Growth Conference on August 12-14, 2025 BioHarvest Sciences Reports Second Quarter 2025 Financial Results BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time BioHarvest Announces Appointment of Sharon Malka to Board of Directors BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound News BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles Technology – Copy Team BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time BIOHARVEST SCIENCES REPORTS Q2 2023 RESULTS DEMONSTRATING CONTINUED GROWTH MOMENTUM BIOHARVEST ANNOUNCES AUGUST 2023 U.S. VINIA SALES EXCEEDED USD $1MILLION HEALTH CANADA GRANTS BIOHARVEST SCIENCES LICENSE FOR VINIA SALES IN CANADA BIOHARVEST SCIENCES INC. ANNOUNCES $11.78M RAISED IN  FIRST TRANCHE OF $13.5M  PRIVATE PLACEMENT BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company BioHarvest Sciences Reports First Quarter 2025 Financial Results BIOHARVEST SCIENCES REPORTS Q3 2023 REVENUE DEMONSTRATING CONTINUED GROWTH MOMENTUM BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar BioHarvest Issues Shareholder Letter and Provides Corporate Update BioHarvest Sciences Announces Voluntary Delisting from CSE BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results BioHarvest In Vitro testing Shows Proprietary Olive Cell Compound  Reduces Fat Accumulation in Liver Cells 2025 CEO Letter to Shareholders BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025 BIOHARVEST SCIENCES TO HOST VIRTUAL SHAREHOLDER UPDATE DECEMBER 13, 2023, 2:30pm ET BIOHARVEST SCIENCES ANNOUNCES MAJOR PRODUCT LAUNCH OF VINIA-BASED FUNCTIONAL COFFEES BIOHARVEST SCIENCES INC. CLOSES FINAL TRANCHE OF OVERSUBSCRIBED $13.5M PRIVATE PLACEMENT Technology Home